International Antiviral Society–USA

Mission

The mission of the International Antiviral Society–USA (IAS–USA) is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Board of Directors

Nonstaff board members serve in a volunteer capacity and are not compensated for their roles in oversight and governance of the organization. As part of its duties, the board oversees the needs assessment, design, development, and evaluation of all educational programs. Visit www.iasusa.org/about/ias-usa-board-of-directors/ for a list of Board of Directors members.

HIV Prevention, Sexual Health, and Primary Care

Sexual Health, HIV Prevention, and Primary Care, a new educational effort from the IAS–USA that premiered in 2019, addresses the rising epidemic of sexually transmitted infections (STIs) in the United States. This course addresses the best practices for maintaining sexual health among adolescents and adults with or at risk for HIV infection. This includes diagnosis, management, and prevention of STIs. The course also addresses other key factors in maintaining sexual health such as HIV prevention strategies, including preexposure prophylaxis (PrEP), antiretroviral therapy during conception and pregnancy, and appropriate vaccines against preventable diseases. Information is presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of STI and HIV/AIDS clinicians and researchers. Visit www.iasusa.org/activities/live-courses/ for more information.

Improving the Management of HIV Disease®: An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

These one-day live courses are designed for HIV specialists who are actively involved in HIV disease management or research. Nationally and internationally recognized faculty provide advanced-level presentations with balanced, timely, scientifically rigorous, and clinically relevant information about HIV disease management. These courses are held in several US cities each year. Visit www.iasusa.org/activities/live-courses/hiv-courses/ for upcoming courses.

Due to the COVID-19 Pandemic, we have transitioned our 2020 HIV courses to virtual, offering 3 in three different time zones.

Webinars

The Cases on the Web (COW) program started as a series of case-driven continuing medical education (CME) activities created to offer physicians convenient online access to top-quality education. The program has evolved into the IAS–USA webinar program, which continues to provide CME credits for physicians.

The IAS–USA offers state-of-the-art CME webinars led by nationally and internationally recognized faculty. Each webinar lasts 75 to 90 minutes and addresses a current topic in HIV infection prevention and management and the treatment of concomitant conditions. Archived webinars offer CME credit for a year.

The COW Board is a select group of experts in the management of HIV and other viral infections who determine the webinar topics that are important to highlight and presenters that are most qualified and best suited to give the webinar. Dedicated to teaching practitioners who are actively involved in medical care for people with HIV or other viral infections, the COW Board ensures that the webinar program remains a relevant and useful educational tool for the IAS–USA audience.

Conference on Retroviruses and Opportunistic Infections


CROI 2020 will be held in Boston, Massachusetts, from March 8 to March 11, 2020.

Topics in Antiviral Medicine™

The IAS–USA publishes the peer-reviewed journal Topics in Antiviral Medicine™ 4 to 6 times a year as a resource for physicians and other health care practitioners who are actively involved in the care of patients with HIV or other viral infections. The journal offers CME credit and is indexed on Index Medicus/MEDLINE. To be added to our email list, please create an account on the IAS–USA website at www.iasusa.org. See the FAQ page for additional information on how to create an account. Subscriptions are complimentary.
Treatment and Testing Guidelines

The IAS–USA sponsors the development of clinical practice guidelines. The guidelines are written by independent volunteer panels of researchers and clinicians from around the world and focus on management issues for which definitive evidence is lacking. Guidelines for viral load testing, antiretroviral therapy, behavioral and biomedical HIV prevention, HIV drug resistance testing, cytomegalovirus infection, and metabolic complications have been published. Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS–USA Antiretroviral Guidelines Panel, are published biannually in the *Journal of the American Medical Association*. Visit www.iasusa.org/resources/guidelines for updates.

Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS–USA Antiretroviral Guidelines Panel, were published in the *Journal of the American Medical Association* in July 2018 (Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA panel. *JAMA.* 2018;320[4]:379-396). JAMA offers free access to the paper at https://jamanetwork.com/journals/jama/article-abstract/2688574. The paper includes updated recommendations for the use of antiretroviral therapy in adults with established HIV infection, including when to start treatment, initial regimens, and changing regimens, along with recommendations for using antiretroviral drugs for preventing HIV among those at risk, including preexposure and postexposure prophylaxis.

Drug Resistance Mutations Projects

Through the HIV Drug Resistance Mutations Panel, the IAS–USA provides regular updates on the mutations associated with resistance to antiretroviral drugs. The information on relevant mutations is collected and reviewed by a panel of acknowledged leaders in the field. This information, last updated in July 2019, is available in *Topics in Antiviral Medicine™*, on pocket reference cards (available from the IAS–USA), and on the IAS–USA website at www.iasusa.org/resources/hiv-drug-resistance-mutations/.

COVID-19: What We Know Today
A Dialogue About the Public Health, Scientific, and Clinical Aspects of the Pandemic

The COVID-19 pandemic has created an urgent need for reliable scientific information. Our understanding of SARS-CoV-2 and COVID-19 disease changes almost daily. In response, the IAS–USA has created a program that will bring together leading experts to discuss the latest science regarding COVID-19 and what the data and research are telling us about the basic science, public health, and clinical aspects of the disease and the consequences of the pandemic.

The live broadcast is offered on a first-come, first-served basis and is not available for Continuing Medical Education credits. The conversations will be available as podcasts and on-demand after they are broadcast on the IAS–USA website, with the warning that the shelf life of COVID-19 information is short right now.

Podcasts

Some past IAS–USA live CME courses are available as podcasts and may be downloaded from the IAS–USA website. Visit www.iasusa.org/resources/podcasts for details and a list of available presentations. Please note that these podcasts do not offer CME credit.

Presentation Slides

The IAS–USA offers a collection of downloadable presentation slides from presentations at conferences or past IAS–USA live courses. Slides may be downloaded as PowerPoint files from the IAS–USA website at www.iasusa.org/resources/key-slides/.

For information about any of these programs, please contact the IAS–USA.

Phone: (415) 544-9400 • Fax: (415) 544-9401
E-mail: registration@iasusa.org • Website: www.iasusa.org